Biotech Analyst Fadia, along with Dr. Justin Long, discuss the factors influencing adoption of Alzheimer’s disease treatments, including Biogen (BIIB)/Eisai’s Leqembi and Lilly’s Kisunla on an Analyst/Industry conference call to be held on November 13 at 11 am.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB: